NCT01617746

Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: University of Glasgow · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study will be to determine if blockade of endothelin 1 signalling via endothelin receptor A using ambrisentan or dual blockade (A\&B) via bosentan can provide protection against methacholine induced bronchoconstriction in asthma.

Detailed description

Endothelin 1 may have a role in the development of acute airway narrowing in asthma. Blockade of the endothelin system may thereby protect against airway narrowing. Two receptors exist for endothelin 1, Endothelin A \& B. Both can be blocked by Bosentan, and the A receptor by ambrisentan. Both medications are currently in use for the treatment of pulmonary arterial hypertension. The investigators will endeavour to examine the potential role of endothelin 1 in the development of airway narrowing in asthma through blockade of the endothelin receptors A\&B through the use of bosentan and ambrisentan.

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	Ambrisentan	5mg od two weeks
DRUG	Bosentan	62.5mg bd two weeks
DRUG	Placebo	bd for two weeks

Timeline

• Start date: 2012-11-01
• Primary completion: 2014-05-01
• Completion: 2015-12-01
• First posted: 2012-06-12
• Last updated: 2012-06-12

Locations

1 site across 1 country: United Kingdom